1
|
Sperry BW, Zein RE, Fendler TJ, Sauer AJ, Khumri TM, Magalski A, Austin BA, Safley D, Kao AC. Stabilization of Rapidly Progressive Cardiac Allograft Vasculopathy Using mTOR Inhibition After Heart Transplantation. J Card Fail 2024; 30:613-617. [PMID: 37992800 DOI: 10.1016/j.cardfail.2023.10.483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2023] [Revised: 10/26/2023] [Accepted: 10/27/2023] [Indexed: 11/24/2023]
Abstract
BACKGROUND Inhibition of the mammalian target of rapamycin (mTor) pathway after heart transplantation has been associated with reduced progression of coronary allograft vasculopathy (CAV). The application of low-dose mTOR inhibition in the setting of modern immunosuppression, including tacrolimus, remains an area of limited exploration. METHODS This retrospective study included patients who received heart transplantation between January 2009 and January 2019 and had baseline, 1-year and 2-3-year coronary angiography with intravascular ultrasound (IVUS). Intimal thickness in 5 segments along the left anterior descending artery was compared across imaging time points in patients who were transitioned to low-dose mTOR inhibitor (sirolimus) vs standard treatment with mycophenolate on a background of tacrolimus. Long-term adverse cardiovascular outcomes (revascularization, severe CAV, retransplant, and cardiovascular death) were also assessed. RESULTS Among 216 patients (mean age 51.5 ± 11.9 years, 77.8% men, 80.1% white), 81 individuals (37.5%) were switched to mTOR inhibition. mTOR inhibition was associated with a reduction in intimal thickness by 0.05 mm (95% CI 0.02-0.07; P < 0.001). This reduction was driven by patients who met the criteria for rapidly progressive CAV 1-year post-transplant (0.12 mm; P = 0.016 for interaction). After a median follow-up of 8.6 (IQR 6.6-11) years, 40 patients had major adverse cardiovascular outcomes. The use of mTOR inhibitors was not significantly associated with cardiovascular outcomes (P = 0.669). CONCLUSION Transitioning patients after heart transplantation to an immunosuppression regimen composed of low-dose mTOR inhibition and tacrolimus was associated with a lack of progression of CAV, particularly in those with rapidly progressive CAV at 1 year, but not with long-term cardiovascular outcomes.
Collapse
Affiliation(s)
- Brett W Sperry
- Saint Luke's Mid America Heart Institute, Kansas City, MO; University of Missouri-Kansas City School of Medicine, Kansas City, MO.
| | - Rayan El Zein
- University of Missouri-Kansas City School of Medicine, Kansas City, MO
| | - Timothy J Fendler
- Saint Luke's Mid America Heart Institute, Kansas City, MO; University of Missouri-Kansas City School of Medicine, Kansas City, MO
| | - Andrew J Sauer
- Saint Luke's Mid America Heart Institute, Kansas City, MO; University of Missouri-Kansas City School of Medicine, Kansas City, MO
| | - Taiyeb M Khumri
- Saint Luke's Mid America Heart Institute, Kansas City, MO; University of Missouri-Kansas City School of Medicine, Kansas City, MO
| | - Anthony Magalski
- Saint Luke's Mid America Heart Institute, Kansas City, MO; University of Missouri-Kansas City School of Medicine, Kansas City, MO
| | - Bethany A Austin
- Saint Luke's Mid America Heart Institute, Kansas City, MO; University of Missouri-Kansas City School of Medicine, Kansas City, MO
| | - David Safley
- Saint Luke's Mid America Heart Institute, Kansas City, MO; University of Missouri-Kansas City School of Medicine, Kansas City, MO
| | - Andrew C Kao
- Saint Luke's Mid America Heart Institute, Kansas City, MO; University of Missouri-Kansas City School of Medicine, Kansas City, MO
| |
Collapse
|
2
|
Harhash AA, Kennedy KF, Fendler TJ, Khumri TM, Nassif ME, Magalski A, Sperry BW. Comparison of Outcomes Among Patients With Cardiogenic Shock Admitted on Weekends Versus Weekdays. Am J Cardiol 2021; 144:20-25. [PMID: 33417875 DOI: 10.1016/j.amjcard.2020.12.061] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/03/2020] [Revised: 12/18/2020] [Accepted: 12/22/2020] [Indexed: 11/30/2022]
Abstract
Cardiogenic shock (CS) is associated with high mortality and often requires involvement of a multidisciplinary provider team to deliver timely care. Care coordination is more difficult on weekends, which may lead to a delay in care. We sought to assess the effect of weekend admissions on outcomes in patients admitted with CS. Patients admitted with CS were identified from 2005 to 2014 in the National Inpatient Sample using ICD9 code 785.51. Baseline demographics, in-hospital procedures, and outcomes were obtained and compared by day of admission. A multivariable model was used to assess the impact of weekend admission on in-hospital mortality. A total of 875,054 CS admissions were identified (age 67.4 ± 15.1 years, 40.2% female, 72.1% Caucasian), with 23% of patients being admitted on weekends. Baseline co-morbidities were similar between groups. Weekend admissions were associated with higher in-hospital mortality (40.6% vs 37.5%) and cardiac arrest (20.3% vs 18.1%, p < 0.001 for both) consistently over the study period. Use of temporary and permanent mechanical support devices and heart transplantation were slightly less common for weekend admissions. In a multivariable model adjusting for relevant confounders, weekend admission was associated with a 10% increased mortality in patients with CS. In conclusion, patients with CS admitted on weekends had higher in-hospital mortality and were slightly less likely to receive mechanical support and advanced therapies compared with those admitted on weekdays. Future studies and health system initiatives should focus on rectifying these disparities with around-the-clock multidisciplinary coordinated care for CS.
Collapse
Affiliation(s)
- Ahmed A Harhash
- Saint Luke's Mid America Heart Institute, Kansas City, Missouri; University of Missouri-Kansas City, Kansas City, Missouri
| | | | - Timothy J Fendler
- Saint Luke's Mid America Heart Institute, Kansas City, Missouri; University of Missouri-Kansas City, Kansas City, Missouri
| | - Taiyeb M Khumri
- Saint Luke's Mid America Heart Institute, Kansas City, Missouri; University of Missouri-Kansas City, Kansas City, Missouri
| | - Michael E Nassif
- Saint Luke's Mid America Heart Institute, Kansas City, Missouri; University of Missouri-Kansas City, Kansas City, Missouri
| | - Anthony Magalski
- Saint Luke's Mid America Heart Institute, Kansas City, Missouri; University of Missouri-Kansas City, Kansas City, Missouri
| | - Brett W Sperry
- Saint Luke's Mid America Heart Institute, Kansas City, Missouri; University of Missouri-Kansas City, Kansas City, Missouri.
| |
Collapse
|
3
|
Sammour Y, Dezorzi C, Austin BA, Borkon AM, Everley MP, Fendler TJ, Khumri TM, Lawhorn SL, Nassif ME, Vodnala D, Magalski A, Kao AC, Sperry BW. PCSK9 Inhibitors in Heart Transplant Patients: Safety, Efficacy, and Angiographic Correlates. J Card Fail 2021; 27:812-815. [PMID: 33753241 DOI: 10.1016/j.cardfail.2021.02.018] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2021] [Revised: 02/08/2021] [Accepted: 02/23/2021] [Indexed: 11/24/2022]
Abstract
BACKGROUND Statins are recommended in heart transplant patients, but are sometimes poorly tolerated. Alternative agents are often considered including proprotein convertase subtilisin/kexin type-9 inhibitors (PCSK9i). We sought to investigate the use of PCSK9i after heart transplantation. METHODS AND RESULTS We identified patients who received a heart transplant from 1999 to 2019 and were started on PCSK9i at our institution. Clinical, laboratory, and coronary angiography with intravascular ultrasound results were compared. Among 65 patients initiated on PCSK9i (48 for statin intolerance and 17 for refractory hyperlipidemia), the median time from transplant was 5.5 years (interquartile range [IQR], 2.8-9.9 years) with a median PCSK9 treatment duration of 1.6 years (IQR, 0.8-3.2 years) and 80% still on treatment. Evolocumab was used in 73.8%, alirocumab in 12.3%, and both in 13.8% owing to insurance coverage. All patients required prior authorization; initial denial occurred in 18.5% and 32.3% had denials in subsequent years. The median low-density lipoprotein cholesterol decreased from 130 mg/dL (IQR, 102-148 mg/dL) to 55 mg/dL (IQR, 35-74 mg/dL) after starting PCSK9i (P < .001), with 72% of patients achieving a low-density lipoprotein cholesterol of <70 mg/dL after treatment. There were also significant reductions of total cholesterol, non-high-density lipoprotein cholesterol, total/high-density lipoprotein cholesterol ratio, and triglycerides, with a modest increase in high-density lipoprotein cholesterol. These changes were durable at latest follow-up. In 33 patients with serial coronary angiography and intravascular ultrasound, PCSK9i were associated with stable coronary plaque thickness and lumen area. CONCLUSIONS Among heart transplant recipients, PCSK9i are effective in lowering cholesterol levels and stabilizing coronary intimal hyperplasia with minimal side effects. Despite favorable effects, access and affordability remain a challenge.
Collapse
Affiliation(s)
- Yasser Sammour
- Saint Luke's Mid America Heart Institute and the University of Kanas City-Missouri, Kansas City, MO
| | - Christopher Dezorzi
- Saint Luke's Mid America Heart Institute and the University of Kanas City-Missouri, Kansas City, MO
| | - Bethany A Austin
- Saint Luke's Mid America Heart Institute and the University of Kanas City-Missouri, Kansas City, MO
| | - A Michael Borkon
- Saint Luke's Mid America Heart Institute and the University of Kanas City-Missouri, Kansas City, MO
| | - Mark P Everley
- Saint Luke's Mid America Heart Institute and the University of Kanas City-Missouri, Kansas City, MO
| | - Timothy J Fendler
- Saint Luke's Mid America Heart Institute and the University of Kanas City-Missouri, Kansas City, MO
| | - Taiyeb M Khumri
- Saint Luke's Mid America Heart Institute and the University of Kanas City-Missouri, Kansas City, MO
| | - Stephanie L Lawhorn
- Saint Luke's Mid America Heart Institute and the University of Kanas City-Missouri, Kansas City, MO
| | - Michael E Nassif
- Saint Luke's Mid America Heart Institute and the University of Kanas City-Missouri, Kansas City, MO
| | - Deepthi Vodnala
- Saint Luke's Mid America Heart Institute and the University of Kanas City-Missouri, Kansas City, MO
| | - Anthony Magalski
- Saint Luke's Mid America Heart Institute and the University of Kanas City-Missouri, Kansas City, MO
| | - Andrew C Kao
- Saint Luke's Mid America Heart Institute and the University of Kanas City-Missouri, Kansas City, MO
| | - Brett W Sperry
- Saint Luke's Mid America Heart Institute and the University of Kanas City-Missouri, Kansas City, MO.
| |
Collapse
|
4
|
Sperry BW, Qarajeh R, Omer MA, Brandt H, Safley D, Borkon AM, Everley MP, Fendler TJ, Khumri TM, Lawhorn SL, Magalski A, Nassif ME, Vodnala D, Kao AC, Austin BA. Influence of Donor Transmitted and Rapidly Progressive Coronary Vascular Disease on Long-Term Outcomes After Heart Transplantation: A Contemporary Intravascular Ultrasound Analysis. J Card Fail 2021; 27:464-472. [PMID: 33358960 DOI: 10.1016/j.cardfail.2020.12.012] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2020] [Revised: 12/14/2020] [Accepted: 12/16/2020] [Indexed: 11/26/2022]
Abstract
BACKGROUND Donor-transmitted atherosclerosis (DTA) and rapidly progressive cardiac allograft vasculopathy (CAV) at 1 year are intravascular ultrasound (IVUS)-derived measures shown to predict adverse cardiovascular outcomes in the setting of early generation immunosuppressive agents. Given the paucity of data on the prognostic value of IVUS-derived measurements in the current era, we sought to explore their association with adverse outcomes after heart transplantation. METHODS AND RESULTS This is a retrospective cohort analysis of patients who underwent heart transplantation at our center between January 2009 and June 2016 with baseline and 1-year IVUS. Five IVUS sections were prospectively analyzed for intimal thickness and lumen area. DTA was defined as maximum intimal thickness of 0.5 mm or greater at baseline, and rapidly progressive CAV as an increase in maximum intimal thickness by 0.5 mm or more at 1 year. Our primary analysis assessed the relationship of IVUS and other clinical data on a composite outcome: coronary intervention, CAV stage 2 or 3 (defined by the International Society for Heart and Lung Transplantation 2010 nomenclature), or cardiovascular death. Among 249 patients (mean age 51.0 ± 12.2 years and 74.3% male) included in the analysis, DTA was detected in 118 patients (51.4%). Over a median follow-up of 6.1 years (interquartile range 4.2-8.0 years), 45 patients met the primary end point (23 percutaneous coronary intervention, 11 CAV 2 or 3, and 11 cardiovascular deaths as first event). DTA and rapidly progressive CAV were not associated with the primary end point, all-cause mortality, or retransplantation. In an additional analysis including post-transplant events, incident rejection was strongly associated with poor outcomes, although cytomegalovirus infection was not. CONCLUSIONS In this contemporary cohort, IVUS-derived DTA and rapidly progressive CAV were not associated with medium- to long-term adverse events after heart transplantation.
Collapse
Affiliation(s)
- Brett W Sperry
- Saint Luke's Mid America Heart Institute, Kansas City, Missouri; University of Missouri-Kansas City School of Medicine, Kansas City, Missouri.
| | - Raed Qarajeh
- University of Missouri-Kansas City School of Medicine, Kansas City, Missouri
| | - Mohamed A Omer
- University of Missouri-Kansas City School of Medicine, Kansas City, Missouri
| | - Hunter Brandt
- Saint Luke's Mid America Heart Institute, Kansas City, Missouri; University of Missouri-Kansas City School of Medicine, Kansas City, Missouri
| | - David Safley
- Saint Luke's Mid America Heart Institute, Kansas City, Missouri; University of Missouri-Kansas City School of Medicine, Kansas City, Missouri
| | - A Michael Borkon
- Saint Luke's Mid America Heart Institute, Kansas City, Missouri; University of Missouri-Kansas City School of Medicine, Kansas City, Missouri
| | - Mark P Everley
- Saint Luke's Mid America Heart Institute, Kansas City, Missouri; University of Missouri-Kansas City School of Medicine, Kansas City, Missouri
| | - Timothy J Fendler
- Saint Luke's Mid America Heart Institute, Kansas City, Missouri; University of Missouri-Kansas City School of Medicine, Kansas City, Missouri
| | - Taiyeb M Khumri
- Saint Luke's Mid America Heart Institute, Kansas City, Missouri; University of Missouri-Kansas City School of Medicine, Kansas City, Missouri
| | - Stephanie L Lawhorn
- Saint Luke's Mid America Heart Institute, Kansas City, Missouri; University of Missouri-Kansas City School of Medicine, Kansas City, Missouri
| | - Anthony Magalski
- Saint Luke's Mid America Heart Institute, Kansas City, Missouri; University of Missouri-Kansas City School of Medicine, Kansas City, Missouri
| | - Michael E Nassif
- Saint Luke's Mid America Heart Institute, Kansas City, Missouri; University of Missouri-Kansas City School of Medicine, Kansas City, Missouri
| | - Deepthi Vodnala
- Saint Luke's Mid America Heart Institute, Kansas City, Missouri; University of Missouri-Kansas City School of Medicine, Kansas City, Missouri
| | - Andrew C Kao
- Saint Luke's Mid America Heart Institute, Kansas City, Missouri; University of Missouri-Kansas City School of Medicine, Kansas City, Missouri
| | - Bethany A Austin
- Saint Luke's Mid America Heart Institute, Kansas City, Missouri; University of Missouri-Kansas City School of Medicine, Kansas City, Missouri
| |
Collapse
|
5
|
Sammour Y, Austin BA, Borkon M, Everley MP, Fendler TJ, Khumri TM, Lawhorn SL, Magalski A, Nassif ME, Vodnala D, Kao AC, Sperry BW. Safety and Effectiveness of PCSK9 Inhibitors in Orthotopic Heart Transplant Patients. J Card Fail 2020. [DOI: 10.1016/j.cardfail.2020.09.071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
6
|
Sperry BW, Khumri TM, Kao AC. Donor-derived cell-free DNA in a heart transplant patient with COVID-19. Clin Transplant 2020; 34:e14070. [PMID: 32856335 PMCID: PMC7460935 DOI: 10.1111/ctr.14070] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2020] [Revised: 08/07/2020] [Accepted: 08/14/2020] [Indexed: 12/24/2022]
Affiliation(s)
- Brett W Sperry
- Saint Luke's Mid America Heart Institute, Kansas City, MO, USA.,The University of Missouri-Kansas City, Kansas City, MO, USA
| | - Taiyeb M Khumri
- Saint Luke's Mid America Heart Institute, Kansas City, MO, USA.,The University of Missouri-Kansas City, Kansas City, MO, USA
| | - Andrew C Kao
- Saint Luke's Mid America Heart Institute, Kansas City, MO, USA.,The University of Missouri-Kansas City, Kansas City, MO, USA
| |
Collapse
|
7
|
Muskula PR, Khumri TM, Main ML. Transesophageal echocardiographic guidance of transcatheter closure of the aortic valve in a patient with left ventricular assist device-related severe aortic regurgitation. Echo Res Pract 2017; 4:I7-I9. [PMID: 28432187 PMCID: PMC5446593 DOI: 10.1530/erp-17-0003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2017] [Accepted: 03/24/2017] [Indexed: 12/01/2022] Open
Affiliation(s)
| | - Taiyeb M Khumri
- Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA
| | - Michael L Main
- Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA
| |
Collapse
|
8
|
Khalid A, Bhatti SK, Al-Amoodi M, House JA, Khumri TM, O'Keefe JH, Main ML. Clinical factors associated with left ventricular ejection fraction disparity in patients with left ventricular dysfunction undergoing multimodality imaging. Mo Med 2012; 109:489-492. [PMID: 23362654 PMCID: PMC6179602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Drug and device therapy for heart failure is increasingly determined based on left ventricular ejection fraction. Significant disparity frequently exists between echocardiographic and nuclear scintigraphic techniques, even when testing is performed nearly simultaneously in clinically stable patients. In 119 patients with left ventricular dysfunction who underwent both echocardiography and stress testing with nuclear imaging within seven days (but with significant disparity in reported left ventricular ejection fraction), we identified four clinical variables which were associated with left ventricular ejection fraction difference. These clinical variables included atrial fibrillation, left ventricular hypertrophy, severe mitral regurgitation and paced rhythm.
Collapse
Affiliation(s)
- Adnan Khalid
- Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA
| | | | | | | | | | | | | |
Collapse
|
9
|
Affiliation(s)
- Ashley R. Moser
- From the University of Missouri-Kansas City School of Medicine (A.R.M.), Saint Luke's Health System (D.H.), and Saint Luke's Mid America Heart Institute (A.M., M.L.M., T.M.K., B.A.A.), Kansas City, MO
| | - Darby Hockman
- From the University of Missouri-Kansas City School of Medicine (A.R.M.), Saint Luke's Health System (D.H.), and Saint Luke's Mid America Heart Institute (A.M., M.L.M., T.M.K., B.A.A.), Kansas City, MO
| | - Anthony Magalski
- From the University of Missouri-Kansas City School of Medicine (A.R.M.), Saint Luke's Health System (D.H.), and Saint Luke's Mid America Heart Institute (A.M., M.L.M., T.M.K., B.A.A.), Kansas City, MO
| | - Michael L. Main
- From the University of Missouri-Kansas City School of Medicine (A.R.M.), Saint Luke's Health System (D.H.), and Saint Luke's Mid America Heart Institute (A.M., M.L.M., T.M.K., B.A.A.), Kansas City, MO
| | - Taiyeb M. Khumri
- From the University of Missouri-Kansas City School of Medicine (A.R.M.), Saint Luke's Health System (D.H.), and Saint Luke's Mid America Heart Institute (A.M., M.L.M., T.M.K., B.A.A.), Kansas City, MO
| | - Bethany A. Austin
- From the University of Missouri-Kansas City School of Medicine (A.R.M.), Saint Luke's Health System (D.H.), and Saint Luke's Mid America Heart Institute (A.M., M.L.M., T.M.K., B.A.A.), Kansas City, MO
| |
Collapse
|
10
|
|
11
|
Khumri TM, Reid KJ, Kosiborod M, Spertus JA, Main ML. Usefulness of left ventricular diastolic dysfunction as a predictor of one-year rehospitalization in survivors of acute myocardial infarction. Am J Cardiol 2009; 103:17-21. [PMID: 19101223 DOI: 10.1016/j.amjcard.2008.08.049] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/03/2008] [Revised: 08/19/2008] [Accepted: 08/19/2008] [Indexed: 12/22/2022]
Abstract
Presence of severe left ventricular (LV) diastolic function has been shown to independently predict risk of heart failure or death after acute myocardial infarction (AMI). We aimed to determine whether common echocardiographic parameters and (LV) diastolic function evaluated during AMI hospitalization can predict the risk of rehospitalization, up to 1 year after AMI. One hundred ninety consecutive patients with AMI, who were prospectively enrolled in a longitudinal post-AMI registry, had survived for 1 year, and had a clinically indicated echocardiogram during the index admission, were included in the study. The independent effect of diastolic dysfunction on 1-year all-cause rehospitalization was assessed using multivariable proportional hazards regression. Average age was 62.5 years, 93% were Caucasian, 66% were men, and mean LV ejection fraction was 46%. At 1 year, 78 patients (41%) had been rehospitalized >or=1 time. In multivariable analysis, presence of severe LV diastolic dysfunction was the only echocardiographic variable that predicted increased risk of rehospitalization 1 year after AMI (hazard ration 3.31, 95% confidence interval 1.26 to 8.69). Seventy-eight percent of patients with severe LV diastolic dysfunction (restrictive diastolic physiology) compared with 30% with normal diastolic function (p = 0.0052) and 37% with nonrestrictive physiology during the index admission were rehospitalized. In conclusion, severe LV diastolic dysfunction is the only echocardiographic predictor of rehospitalization in survivors of AMI and routine assessment of diastolic function during AMI hospitalization can provide additional prognostic risk stratification at dismissal.
Collapse
Affiliation(s)
- Taiyeb M Khumri
- Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA
| | | | | | | | | |
Collapse
|
12
|
Khumri TM, Walker BL, Magalski A, Morris BA, Coggins TR, Kusnetzky LL, House JA, Main ML. Combined Assessment of Myocardial Perfusion and Diastolic Function Enhances Risk Stratification in Patients with Anterior Wall Myocardial Infarction. Echocardiography 2009; 26:61-5. [DOI: 10.1111/j.1540-8175.2008.00750.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
13
|
Kusnetzky LL, Khalid A, Khumri TM, Moe TG, Jones PG, Main ML. Acute Mortality in Hospitalized Patients Undergoing Echocardiography With and Without an Ultrasound Contrast Agent. J Am Coll Cardiol 2008; 51:1704-6. [DOI: 10.1016/j.jacc.2008.03.006] [Citation(s) in RCA: 110] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/16/2008] [Revised: 02/26/2008] [Accepted: 03/05/2008] [Indexed: 11/27/2022]
|
14
|
Thibodeau JB, Pillarisetti J, Khumri TM, Jones PG, Main ML. Mortality rates and clinical predictors of reduced survival after cardioverter defibrillator implantation. Am J Cardiol 2008; 101:861-4. [PMID: 18328854 DOI: 10.1016/j.amjcard.2007.10.048] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/28/2007] [Revised: 10/02/2007] [Accepted: 10/02/2007] [Indexed: 11/30/2022]
Abstract
We aimed to identify mortality rates and clinical predictors of reduced survival in a large cohort of patients after implantation of an implantable cardioverter-defibrillator (ICD). Although existing data from clinical trials report annual mortality after ICD implantation from 2% to 9%, there are few data available on mortality rates or predictors of reduced survival in this patient population in clinical practice. In this single-center, retrospective analysis of 286 patients who underwent ICD implantation between June 1, 2000 and December 30, 2003, candidate predictors of mortality were assessed and subjected to multivariable analysis. Outcomes were documented using the Social Security Death Master File and hospital medical records. Overall annualized mortality was 11.3% after ICD implantation. Mortality rates in patients with left ventricular ejection fraction (LVEF) <25% were 27.2% at 1 year and 50.5% at 3 years. Digoxin (hazard ratio 1.86, 95% confidence interval [CI] 1.21 to 2.86, p = 0.0046) and loop diuretics (hazard ratio 1.59, 95% CI 1.06 to 2.38, p = 0.024) were associated with reduced survival. Angiotensin-converting enzyme inhibitor or aldosterone receptor blocker use was associated with reduced mortality (hazard ratio 0.50, 95% CI 0.31 to 0.80, p = 0.0038). In conclusion, mortality after ICD implantation is higher than demonstrated in primary or secondary prevention ICD trials; LVEF remains a potent predictor of mortality after ICD implantation, particularly in patients with an LVEF <25%; loop diuretic and digoxin use is associated with an approximate twofold increase in mortality in this population; and angiotensin-converting enzyme inhibitor or aldosterone receptor blocker use is associated with improved survival after ICD implantation.
Collapse
|
15
|
|
16
|
Rader VJ, Khumri TM, Idupulapati M, Stoner CN, Magalski A, Main ML. Clinical Predictors of Left Atrial Thrombus and Spontaneous Echocardiographic Contrast in Patients with Atrial Fibrillation. J Am Soc Echocardiogr 2007; 20:1181-5. [PMID: 17566700 DOI: 10.1016/j.echo.2007.02.010] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/20/2006] [Indexed: 10/23/2022]
Abstract
OBJECTIVES We sought to determine the relationship between clinical risk factors for systemic thromboembolism in patients with atrial fibrillation and the prevalence of left atrial (LA) spontaneous echocontrast (SEC) and LA thrombus (LAT). BACKGROUND Atrial fibrillation is associated with an increased risk of systemic thromboembolism. LA SEC and LAT also predict thromboembolic events. The relationship between clinical risk factors for systemic thromboembolism and prevalence of LA SEC and LAT is unknown. METHODS In all, 524 patients with atrial fibrillation underwent transesophageal echocardiography between August 2000 and March 2005. Clinical risk factors for systemic thromboembolism were determined for each patient. A CHADS(2) score ranging from 0 to 6 was calculated for each patient as: congestive heart failure = 1 point; hypertension = 1 point; age 75 years or older = 1 point; diabetes mellitus = 1 point; and history of stroke including transient ischemic attack or systemic embolism = 2 points. Transesophageal echocardiography reports were reviewed for the presence of LA SEC and LAT. Univariate and multivariable models were structured to assess which clinical risk factors predicted the presence of LA SEC or LAT. RESULTS In a multivariable model, age 75 years or older, previous thromboembolic event, and left ventricular ejection fraction (LVEF) less than 40% predicted LA SEC, whereas LVEF less than 40% was the only predictor of LAT. LA SEC was present in 24% of patients with a CHADS(2) score of 0, but was present in 58% with a CHADS(2) score of 5 or 6 (P < .0001). LAT was present in 3% percent of patients with a CHADS(2) score of 0, but in 17% of patients with a CHADS(2) score of 5 or 6 (P = .0026). CONCLUSION Age 75 years or older, previous thromboembolic event, and LVEF less than 40% predict presence of LA SEC. LVEF less than 40% is the only multivariate predictor of LAT. The prevalence of LA SEC and LAT increases with increasing CHADS(2) score.
Collapse
|
17
|
Khumri TM, Thibodeau JB, Main ML. Transesophageal echocardiographic diagnosis of left atrial appendage occluder device infection. Eur J Echocardiogr 2007; 9:565-6. [PMID: 17681493 DOI: 10.1016/j.euje.2007.06.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The safety and efficacy of a left atrial appendage closure device is currently under evaluation in a large-scale multi-center clinical trial. We report an initial case of left atrial appendage occluder device infection with Staphylococcus aureus; transesophageal echocardiography played a pivotal role in diagnosis and treatment.
Collapse
Affiliation(s)
- Taiyeb M Khumri
- Mid America Heart Institute, 4330 Wornall Road, Suite 2000, Kansas City, MO 64111, USA
| | | | | |
Collapse
|
18
|
Khumri TM, Idupulapati M, Rader VJ, Nayyar S, Stoner CN, Main ML. Clinical and echocardiographic markers of mortality risk in patients with atrial fibrillation. Am J Cardiol 2007; 99:1733-6. [PMID: 17560884 DOI: 10.1016/j.amjcard.2007.01.055] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/20/2006] [Revised: 01/17/2007] [Accepted: 01/17/2007] [Indexed: 10/23/2022]
Abstract
Atrial fibrillation (AF) is independently associated with increases in cardiovascular and all-cause mortality. Although cardiovascular co-morbidities predict stroke risk in AF, their relation with mortality has not been well described. To identify clinical and echocardiographic markers of mortality in patients with AF, 524 patients with AF underwent transesophageal echocardiography from August 2000 to March 2005. Clinical risk factors for systemic thromboembolism were determined for each patient. A CHADS2 (congestive heart failure, hypertension, age>75 years, diabetes, and previous stroke or transient ischemic attack) score ranging from 0 to 6 was calculated for each patient. Transesophageal echocardiographic reports were reviewed for the presence of left atrial spontaneous echocardiographic contrast, left atrial thrombus, the left ventricular ejection fraction, aortic arch atheroma, and the presence and severity of mitral regurgitation. Mortality data were obtained from the Social Security Death Master File. Univariate and multivariate models were structured to assess which variables predicted mortality. In a multivariate model, a history of heart failure, age>75 years, the absence of systemic anticoagulation with warfarin, the presence of left atrial spontaneous echocardiographic contrast, and greater than moderate mitral regurgitation were independent predictors of mortality. Increasing CHADS2 score was also an independent predictor of mortality. A CHADS2 score of 5 or 6 was associated with a >50-fold increase in mortality compared with patients with CHADS2 scores of 0. In conclusion, a history of heart failure, age>or=75 years, the absence of chronic oral anticoagulation, a CHADS2 score>0, and greater than moderate mitral regurgitation are independent predictors of mortality in patients with AF.
Collapse
|
19
|
Khumri TM, Nayyar S, Idupulapati M, Magalski A, Stoner CN, Kusnetzky LL, Kosiborod M, Spertus JA, Main ML. Usefulness of myocardial contrast echocardiography in predicting late mortality in patients with anterior wall acute myocardial infarction. Am J Cardiol 2006; 98:1150-5. [PMID: 17056316 DOI: 10.1016/j.amjcard.2006.05.045] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/21/2006] [Revised: 05/17/2006] [Accepted: 05/17/2006] [Indexed: 11/17/2022]
Abstract
We investigated whether myocardial contrast echocardiography (MCE) performed soon after acute myocardial infarction (AMI) improves risk stratification for late mortality. MCE after AMI identifies microvascular "no-reflow" and predicts early outcomes; however, the predictive value of MCE for late mortality is unknown. One hundred sixty-seven patients with anterior AMI and left ventricular dysfunction underwent MCE 2 days after admission, and a perfusion score index (PSI) was calculated. Long-term follow-up (mean 39 months) was available for all patients. Patients with normal and abnormal perfusion had similar baseline characteristics. Myocardial contrast echocardiographic PSI was a predictor of mortality as a continuous variable (odds ratio 3.2 for each 1.0 increase in PSI, 95% confidence interval 1.1 to 9.7, p = 0.04). In a logistic regression model, age (odds ratio 2.6 per decade, 95% confidence interval 1.6 to 4.4, p = 0.0002) and PSI (odds ratio 4.5 for each 1.0 increase in PSI, 95% confidence interval 1.3 to 15.4, p = 0.02) were the only significant predictors of mortality. In a subanalysis comparing patients >70 years old with abnormal PSI with all other patients, Kaplan-Meier estimates showed a marked difference in survival over a mean follow-up of 39 months (24% vs 4% mortality, p = 0.0002). In conclusion, MCE refines risk stratification soon after anterior AMI in patients with left ventricular dysfunction. Patients at very high and very low risk of mortality can be identified, and myocardial contrast echocardiographic data are incrementally useful compared with existing clinical and angiographic variables.
Collapse
|
20
|
Nayyar S, Magalski A, Khumri TM, Idupulapati M, Stoner CN, Kusnetzky LL, Coggins TR, Morris BA, Main ML. Contrast administration reduces interobserver variability in determination of left ventricular ejection fraction in patients with left ventricular dysfunction and good baseline endocardial border delineation. Am J Cardiol 2006; 98:1110-4. [PMID: 17027582 DOI: 10.1016/j.amjcard.2006.05.038] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/20/2006] [Revised: 05/14/2006] [Accepted: 05/14/2006] [Indexed: 11/16/2022]
Abstract
Echocardiographic contrast agents improve endocardial border delineation in patients with technically difficult baseline studies. With medical and device therapy for heart failure increasingly based on left ventricular (LV) ejection fraction (EF) partition values, the accurate and reproducible assessment of LV function is necessary. It was hypothesized that routine contrast enhancement would significantly reduce interobserver variability in the determination of LVEFs in a cohort of patients with LV dysfunction and good baseline endocardial delineation. All patients underwent baseline noncontrast studies followed by contrast-enhanced imaging using Definity. Two experienced echocardiographers, blinded to the clinical data, determined LVEFs using 4 different techniques: noncontrast estimated (NCE), noncontrast calculated (NCC), contrast estimated (CE), and contrast calculated (CC). Using a mixed-model procedure that allows for fixed and random events, the variance due to error and that due to the patient was obtained (interclass correlation). The proportion of variation due to the reader was calculated as 1--interclass correlation. Mean standardized percentage differences ([reader 1 EF--reader 2 EF]/mean EF) were also calculated for each method. The proportion of variation due to the reader was smallest in the CC group and largest in the NCC group (NCE = 0.21, NCC = 0.33, CE = 0.25, CC = 0.11). The results were similar when only patients with NCE EFs >or=20% and <or=50% were analyzed (NCE = 0.29, NCC = 0.47, CE = 0.33, CC = 0.15). The mean standardized percentage difference between readers was smallest in the CC group for all patients and for those with NCE EFs >or=20% and <or=50%. In conclusion, contrast administration reduces interobserver variability in LVEF assessment, even in patients with good baseline endocardial border delineation, and should be used routinely regardless of the perceived adequacy of baseline images, especially if the LVEF is >or=20% and <or=50%.
Collapse
Affiliation(s)
- Sunil Nayyar
- Mid America Heart Institute, Kansas City, Missouri, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Khumri TM, Joslin NB, Nayyar S, Main ML. Transesophageal echocardiographic diagnosis of Aspergillus fumigatus aortitis after percutaneous coronary intervention. J Am Soc Echocardiogr 2006; 19:1072.e9-11. [PMID: 16880107 DOI: 10.1016/j.echo.2006.03.029] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/14/2005] [Indexed: 11/29/2022]
Abstract
Aspergillus aortitis is an uncommon infection with high mortality and has been reported in patients after cardiopulmonary bypass. We report the first case of Aspergillus aortitis in an immunocompetent man immediately after percutaneous coronary intervention to an aortocoronary bypass graft. In this case, transesophageal echocardiography played a pivotal role in diagnosis.
Collapse
|